Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A review of the venous thrombotic issues associated with multiple myeloma.

Expert review of hematology - 1 Jul 2016

Fotiou Despina, Gerotziafas Grigoris, Kastritis Efstathios, Dimopoulos Meletios A, Terpos Evangelos

Abstract excerpt

INTRODUCTION: Patients with multiple myeloma (MM) have an increased risk of venous thromboembolic (VTE) complications. The first reports of high VTE rates date back to 1999 but became more apparent with the introduction of novel agents in the treatment of MM and mostly with immunomodulatory drugs (IMiDs; thalidomide, lenalidomide and pomalidomide). AREAS COVERED: Currently thromboprophylaxis is recommended for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Factors

Share to Multiple Myeloma

Share to Risk Factors

Share to Venous Thromboembolism

Share to Warfarin

Source

Identifiers

PMID: 27232265
DOI: 10.1080/17474086.2016.1194750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A review of the venous thrombotic issues associated with multiple myeloma.PMID 27232265Read ↗

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.Semantic proximity Read ↗

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.Semantic proximity Read ↗

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.Semantic proximity Read ↗

Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.Semantic proximity Read ↗

Two cases of proteasome inhibitors related thrombotic microangiopathies and literature reviewSemantic proximity Read ↗

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.Semantic proximity Read ↗

Thrombotic and bleeding complications in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.Semantic proximity Read ↗

Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.Semantic proximity Read ↗

Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer.Semantic proximity Read ↗

[Analysis of risk factors for thromboembolism in patients with JAK2V617F gene mutation positive myeloproliferative neoplasms].Semantic proximity Read ↗

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.